Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) (Lancet, 2021)

(untitled) - Flaxman, A; Marchevsky, NG; Jenkin, D; Aboagye, J; Aley, PK; Angus, B; Belij-Rammerstorfer, S; Bibi, S; Bittaye, M; Cappuccini, F; Cicconi, P; Clutterbuck, EA; et al.